BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 7904670)

  • 1. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates.
    Lefrère JJ; Mariotti M; Thauvin M
    Lancet; 1994 Jan; 343(8891):211-2. PubMed ID: 7904670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human parvovirus B19 in clotting factor concentrates: B19 DNA detection by the nested polymerase chain reaction.
    Zakrzewska K; Azzi A; Patou G; Morfini M; Rafanelli D; Pattison JR
    Br J Haematol; 1992 Jul; 81(3):407-12. PubMed ID: 1390215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction.
    McOmish F; Yap PL; Jordan A; Hart H; Cohen BJ; Simmonds P
    J Clin Microbiol; 1993 Feb; 31(2):323-8. PubMed ID: 8432819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate.
    Yee TT; Cohen BJ; Pasi KJ; Lee CA
    Br J Haematol; 1996 May; 93(2):457-9. PubMed ID: 8639448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of human parvovirus B19 DNA detection in blood donors.
    Yoto Y; Kudoh T; Haseyama K; Suzuki N; Oda T; Katoh T; Takahashi T; Sekiguchi S; Chiba S
    Br J Haematol; 1995 Dec; 91(4):1017-8. PubMed ID: 8547113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should measures be taken to reduce the risk of human parvovirus (B19) infection by transfusion of blood components and clotting factor concentrates?
    Mosley JW
    Transfusion; 1994 Sep; 34(9):744-6. PubMed ID: 8091460
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of human parvovirus B19 DNA contamination of factor VIII products.
    Matsunaga Y
    Dev Biol Stand; 1996; 88():217. PubMed ID: 9119140
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of digoxigenin-labelled probes for the detection of B19 parvovirus DNA in batches of blood products.
    Lefrère JJ; Mariotti M
    Cell Mol Biol (Noisy-le-grand); 1995 Nov; 41(7):985-8. PubMed ID: 8595378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transmission of human parvovirus B19 by plasma derived factor VIII concentrates.
    Laurian Y; Dussaix E; Parquet A; Chalvon-Demersay A; d'Oiron R; Tchernia G
    Nouv Rev Fr Hematol (1978); 1994 Dec; 36(6):449-53. PubMed ID: 7753615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of human parvovirus B19 and TT virus in a group of young haemophiliacs in South Africa.
    Rubinstein R; Karabus CD; Smuts H; Kolia F; Van Rensburg EJ
    Haemophilia; 2000 Mar; 6(2):93-7. PubMed ID: 10781195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Transmission of parvovirus B19 by blood and blood components].
    Schwarz TF
    Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():27-31. PubMed ID: 8000251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Severe parvovirus B19 infection in an immunocompetent child with hemophilia A].
    Coumau E; Peynet J; Harzic M; Béal G; Castaigne S; Leverger G; Foucaud P
    Arch Pediatr; 1996 Jan; 3(1):35-9. PubMed ID: 8745824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serological and virological markers of human parvovirus B19 infection in sera of hemophiliacs.
    Grosse-Bley A; Eis-Hübinger AM; Kaiser R; Oldenburg J; Brackmann HH; Schwarz TF; Schneweis KE
    Thromb Haemost; 1994 Oct; 72(4):503-7. PubMed ID: 7878623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies.
    Prikhod'ko GG; Vasilyeva I; Reyes H; Wong S; Brown KE; Jameson T; Busby TF
    Transfusion; 2005 Jun; 45(6):1011-9. PubMed ID: 15935001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parvovirus B19 antibodies in patients with haemophilia A.
    Peerlinck K; Goubau P; Reybrouck R; Desmyter J; Vermylen J
    Thromb Haemost; 1995 Mar; 73(3):555-6. PubMed ID: 7667846
    [No Abstract]   [Full Text] [Related]  

  • 16. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
    Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M; Musso R; Santoro R; Schiavoni M
    Transfusion; 1997 May; 37(5):517-22. PubMed ID: 9149778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Blood Transfusion on the Prevalence of HHpgV-1, HPgV-1, and B19V Among Iranian HCV-infected Patients With Hemophilia.
    Agi E; Hojjatipour S; Namvar A; Bolhassani A
    J Pediatr Hematol Oncol; 2020 May; 42(4):e213-e218. PubMed ID: 31972722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of antibodies against parvovirus B19 in Norwegians with congenital coagulation factor defects treated with plasma products from small donor pools.
    Rollag H; Patou G; Pattison JR; Degré M; Evensen SA; Fröland SS; Glomstein A
    Scand J Infect Dis; 1991; 23(6):675-9. PubMed ID: 1815327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
    Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
    Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transfusion-transmitted disease.
    Lee CA
    Baillieres Clin Haematol; 1996 Jun; 9(2):369-94. PubMed ID: 8800511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.